secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuvation Bio Inc. (NUVB)
CIK:        0001811063
Form:       8-K
Filed at:   2024-01-08T23:59:59+00:00
Accession:  0001193125-24-004426
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Nuvation Bio appoints Robert Mashal, M.D. to board as Class II director
-----------------------------------------------------------------------

- Dr. Mashal appointed to fill vacant board seat effective Jan. 8, 2024; term expires at 2026 annual meeting.
- He is a former global head of strategy for immunology/oncology at Sanofi and a board-certified medical oncologist.
- Received initial option grant of $770,000 in Class A common stock vesting monthly over three years.
- Also eligible for annual cash retainer of $40,000; no committee assignment as of filing date.
- Board determined Dr. Mashal qualifies as independent under NYSE listing rules.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1811063/000119312524004426/0001193125-24-004426-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1811063/000119312524004426/d685245d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-004426

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer